These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31671315)

  • 1. CSF β-amyloid predicts early cerebellar atrophy and is associated with a poor prognosis in multiple sclerosis.
    Pietroboni AM; Schiano di Cola F; Colombi A; Carandini T; Fenoglio C; Ghezzi L; De Riz MA; Triulzi F; Scarpini E; Padovani A; Galimberti D
    Mult Scler Relat Disord; 2020 Jan; 37():101462. PubMed ID: 31671315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
    Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low CSF β-amyloid levels predict early regional grey matter atrophy in multiple sclerosis.
    Pietroboni AM; Colombi A; Carandini T; Contarino VE; Ghezzi L; Fumagalli GG; Arighi A; Fenoglio C; De Riz MA; Triulzi F; Scarpini E; Galimberti D
    Mult Scler Relat Disord; 2020 Apr; 39():101899. PubMed ID: 31884385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gray matter atrophy is related to long-term disability in multiple sclerosis.
    Fisniku LK; Chard DT; Jackson JS; Anderson VM; Altmann DR; Miszkiel KA; Thompson AJ; Miller DH
    Ann Neurol; 2008 Sep; 64(3):247-54. PubMed ID: 18570297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF β-amyloid predicts prognosis in patients with multiple sclerosis.
    Pietroboni AM; Caprioli M; Carandini T; Scarioni M; Ghezzi L; Arighi A; Cioffi S; Cinnante C; Fenoglio C; Oldoni E; De Riz MA; Basilico P; Fumagalli GG; Colombi A; Giulietti G; Serra L; Triulzi F; Bozzali M; Scarpini E; Galimberti D
    Mult Scler; 2019 Aug; 25(9):1223-1231. PubMed ID: 30084711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
    Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
    Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.
    Meijboom R; York EN; Kampaite A; Harris MA; White N; Valdés Hernández MDC; Thrippleton MJ; MacDougall NJJ; Connick P; Hunt DPJ; Chandran S; Waldman AD;
    PLoS One; 2023; 18(7):e0288967. PubMed ID: 37506096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction.
    Anderson VM; Fisniku LK; Altmann DR; Thompson AJ; Miller DH
    Mult Scler; 2009 Jul; 15(7):811-7. PubMed ID: 19465449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of single-subject grey matter networks in early multiple sclerosis.
    Fleischer V; Gonzalez-Escamilla G; Pareto D; Rovira A; Sastre-Garriga J; Sowa P; Høgestøl EA; Harbo HF; Bellenberg B; Lukas C; Ruggieri S; Gasperini C; Uher T; Vaneckova M; Bittner S; Othman AE; Collorone S; Toosy AT; Meuth SG; Zipp F; Barkhof F; Ciccarelli O; Groppa S
    Brain; 2024 Jan; 147(1):135-146. PubMed ID: 37642541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis.
    D'Ambrosio A; Pagani E; Riccitelli GC; Colombo B; Rodegher M; Falini A; Comi G; Filippi M; Rocca MA
    Mult Scler; 2017 Aug; 23(9):1194-1203. PubMed ID: 27760859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
    Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA
    Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of global and regional gray matter volume decrease in multiple sclerosis.
    Grothe M; Lotze M; Langner S; Dressel A
    J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis.
    Hofstetter L; Naegelin Y; Filli L; Kuster P; Traud S; Smieskova R; Mueller-Lenke N; Kappos L; Gass A; Sprenger T; Penner IK; Nichols TE; Vrenken H; Barkhof F; Polman C; Radue EW; Borgwardt SJ; Bendfeldt K
    Mult Scler; 2014 Feb; 20(2):202-13. PubMed ID: 23804554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attention and processing speed performance in multiple sclerosis is mostly related to thalamic volume.
    Bisecco A; Stamenova S; Caiazzo G; d'Ambrosio A; Sacco R; Docimo R; Esposito S; Cirillo M; Esposito F; Bonavita S; Tedeschi G; Gallo A
    Brain Imaging Behav; 2018 Feb; 12(1):20-28. PubMed ID: 28083844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cerebellar damage in explaining disability and cognition in multiple sclerosis phenotypes: a multiparametric MRI study.
    Bonacchi R; Meani A; Pagani E; Marchesi O; Filippi M; Rocca MA
    J Neurol; 2022 Jul; 269(7):3841-3857. PubMed ID: 35230471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
    Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI.
    Mühlau M; Buck D; Förschler A; Boucard CC; Arsic M; Schmidt P; Gaser C; Berthele A; Hoshi M; Jochim A; Kronsbein H; Zimmer C; Hemmer B; Ilg R
    Mult Scler; 2013 Oct; 19(11):1485-92. PubMed ID: 23462349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study.
    Bergsland N; Horakova D; Dwyer MG; Uher T; Vaneckova M; Tyblova M; Seidl Z; Krasensky J; Havrdova E; Zivadinov R
    Neuroimage Clin; 2018; 17():444-451. PubMed ID: 29159057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes.
    Pietroboni AM; Carandini T; Colombi A; Mercurio M; Ghezzi L; Giulietti G; Scarioni M; Arighi A; Fenoglio C; De Riz MA; Fumagalli GG; Basilico P; Serpente M; Bozzali M; Scarpini E; Galimberti D; Marotta G
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):280-287. PubMed ID: 30343433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.